Christopher J Hawkey

Summary

Affiliation: University of Nottingham
Country: UK

Publications

  1. ncbi Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use
    Loren Laine
    University of Southern California School of Medicine, Los Angeles 90033, USA
    Gastroenterology 124:288-92. 2003
  2. ncbi Endoscopic evaluation of the gastro-duodenal tolerance of short-term analgesic treatment with 25 mg diclofenac-K liquid capsules
    C Hawkey
    Digestive Diseases Centre, Nottingham University Hospital, UK
    Aliment Pharmacol Ther 35:819-27. 2012
  3. ncbi Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance
    C J Hawkey
    University Hospital, Nottingham, UK
    Aliment Pharmacol Ther 13:695-702. 1999
  4. ncbi What consideration should be given to Helicobacter pylori in treating nonsteroidal anti-inflammatory drug ulcers?
    C J Hawkey
    Division of Gastroenterology, University Hospital, Nottingham, UK
    Eur J Gastroenterol Hepatol 12:S17-20. 2000
  5. ncbi Nonsteroidal anti-inflammatory drug gastropathy
    C J Hawkey
    Division of Gastroenterology, University Hospital Nottingham, Queen s Medical Centre, Nottingham, England
    Gastroenterology 119:521-35. 2000
  6. ncbi Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans
    C J Hawkey
    Department of Gastroenterology, University Hospital, Queen s Medical Centre, Nottingham, UK
    Aliment Pharmacol Ther 15:1-9. 2001
  7. ncbi Stem cell transplantation for Crohn's disease
    Christopher J Hawkey
    Wolfson Digestive Diseases Centre, University Hospital, Nottingham NG7 2UH, UK
    Best Pract Res Clin Haematol 17:317-25. 2004
  8. ncbi Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis
    Christopher J Hawkey
    Wolfson Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom
    Clin Gastroenterol Hepatol 4:57-66. 2006
  9. ncbi COX-2 chronology
    C J Hawkey
    Wolfson Digestive Diseases Centre, University of Nottingham, University Hospital, Nottingham, NG7 2UH, UK
    Gut 54:1509-14. 2005
  10. ncbi Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study
    C J Hawkey
    University Hospital, Nottingham, United Kingdom
    Gut 52:820-6. 2003

Detail Information

Publications88

  1. ncbi Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use
    Loren Laine
    University of Southern California School of Medicine, Los Angeles 90033, USA
    Gastroenterology 124:288-92. 2003
    ..We performed a post hoc analysis of serious lower GI clinical events with a nonselective NSAID and a COX-2-selective agent in a prospective, double-blind, randomized GI outcomes trial...
  2. ncbi Endoscopic evaluation of the gastro-duodenal tolerance of short-term analgesic treatment with 25 mg diclofenac-K liquid capsules
    C Hawkey
    Digestive Diseases Centre, Nottingham University Hospital, UK
    Aliment Pharmacol Ther 35:819-27. 2012
    ..Diclofenac-potassium (diclofenac--K) 25 mg liquid capsule is absorbed more quickly than the tablet formulation. It offers potential for rapid pain relief, but may alter gastro-duodenal tolerability...
  3. ncbi Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance
    C J Hawkey
    University Hospital, Nottingham, UK
    Aliment Pharmacol Ther 13:695-702. 1999
    ..Reluctance to accept that there may be specific circumstances where H. pylori is beneficial may arise because of the psychological process of cognitive dissonance...
  4. ncbi What consideration should be given to Helicobacter pylori in treating nonsteroidal anti-inflammatory drug ulcers?
    C J Hawkey
    Division of Gastroenterology, University Hospital, Nottingham, UK
    Eur J Gastroenterol Hepatol 12:S17-20. 2000
    ..H. pylori eradication should not be used universally or in high-risk gastric ulcer patients who require management with acid suppression...
  5. ncbi Nonsteroidal anti-inflammatory drug gastropathy
    C J Hawkey
    Division of Gastroenterology, University Hospital Nottingham, Queen s Medical Centre, Nottingham, England
    Gastroenterology 119:521-35. 2000
    ..Their place in therapy, compared with use of misoprostol or proton pump inhibitors, is currently emerging. Future competitors may include nitric oxide-donating, zwitterionic, or R-enantiomer NSAIDs...
  6. ncbi Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans
    C J Hawkey
    Department of Gastroenterology, University Hospital, Queen s Medical Centre, Nottingham, UK
    Aliment Pharmacol Ther 15:1-9. 2001
    ..Overall, the findings from these studies suggest that, as a result of cyclooxygenase-1 sparing, rofecoxib is significantly less gastrotoxic than non-selective NSAIDs, and may not differ from placebo...
  7. ncbi Stem cell transplantation for Crohn's disease
    Christopher J Hawkey
    Wolfson Digestive Diseases Centre, University Hospital, Nottingham NG7 2UH, UK
    Best Pract Res Clin Haematol 17:317-25. 2004
    ..A clinical trial to determine the value of stem cell transplantation in Crohn's disease has been set up under the supervision of the European Group for Blood and Marrow Transplantation...
  8. ncbi Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis
    Christopher J Hawkey
    Wolfson Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom
    Clin Gastroenterol Hepatol 4:57-66. 2006
    ..The aim of this study was to evaluate the gastrointestinal safety of lumiracoxib, a novel selective cyclooxygenase-2 inhibitor...
  9. ncbi COX-2 chronology
    C J Hawkey
    Wolfson Digestive Diseases Centre, University of Nottingham, University Hospital, Nottingham, NG7 2UH, UK
    Gut 54:1509-14. 2005
    ..In this paper I therefore present an historical perspective so that the lessons of the past may be applied to the present...
  10. ncbi Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study
    C J Hawkey
    University Hospital, Nottingham, United Kingdom
    Gut 52:820-6. 2003
    ..This study compared the incidence of endoscopically detected gastroduodenal ulcers in rheumatoid arthritis patients treated with rofecoxib or a non-selective NSAID...
  11. ncbi Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials
    C J Hawkey
    Division of Gastroenterology, University Hospital, Queen s Medical Centre, Nottingham NG7 2UH, UK
    Aliment Pharmacol Ther 15:1593-601. 2001
    ..Highly selective inhibitors of the inducible cyclooxygenase-2 enzyme (coxibs) have been associated with less gastrotoxicity than nonselective NSAIDs in clinical studies...
  12. ncbi Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease
    C J Hawkey
    Division of Gastroenterology, University Hospital, Queen s Medical Centre, Nottingham, UK
    Aliment Pharmacol Ther 17:1065-74. 2003
    ..A double-blind, randomized study was designed to determine whether rabeprazole- and omeprazole-based triple therapy regimens are therapeutically equivalent in the eradication of Helicobacter pylori...
  13. ncbi Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors
    C J Hawkey
    Division of Gastroenterology, Queen s Medical Centre, University Hospital Nottingham, Nottingham, UK
    Gut 52:600-8. 2003
    ..In this article, strategies for subgroups that take account of non-specific gastrointestinal risks, minimisation of residual risk, and the importance of non-gastrointestinal toxicity are suggested, and areas for research identified...
  14. ncbi Non-steroidal anti-inflammatory drugs: who should receive prophylaxis?
    C J Hawkey
    Wolfson Digestive Diseases Centre, Institute of Clinical Research, Nottingham University, University Hospital, Nottingham, UK
    Aliment Pharmacol Ther 20:59-64. 2004
    ..Recent data show that PPI and COX-2 inhibitors can play complementary roles in the management of patients with moderate to severe dyspepsia and at high risk of ulcer complications...
  15. ncbi Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis
    Christopher C Hawkey
    University Hospital Nottingham, Nottingham, United Kingdom
    J Rheumatol 31:1804-10. 2004
    ..The COX-2 selective inhibitor celecoxib was included as an active control...
  16. ncbi Cyclooxygenase inhibition: between the devil and the deep blue sea
    C J Hawkey
    Queen s Medical Centre, University Hospital, Nottingham, UK
    Gut 50:III25-30. 2002
    ..Between them, aspirin and non-aspirin NSAIDs may account for more than half of all episodes of ulcer bleeding and perforation...
  17. ncbi Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs
    C J Hawkey
    Division of Gastroenterology University Hospital, Nottingham NG7 2UH, UK
    Gut 46:310-1. 2000
    ..To determine whether Helicobacter pylori is an independent risk factor for bleeding peptic ulcer in users of non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin...
  18. ncbi Ibuprofen versus other non-steroidal anti-inflammatory drugs: use in general practice and patient perception
    J M Seager
    Division of Gastroenterology, University Hospital, Nottingham, UK
    Aliment Pharmacol Ther 14:187-91. 2000
    ..To investigate whether ibuprofen was as well-regarded by patients as other non-steroidal anti-inflammatory drugs (NSAIDs)...
  19. ncbi Pharmacoepidemiology of non-steroidal anti-inflammatory drug use in Nottingham general practices
    D J Cullen
    Division of Gastroenterology, University Hospital, Nottingham, UK
    Aliment Pharmacol Ther 14:177-85. 2000
    ..To investigate the pharmacoepidemiology of NSAID usage in Nottingham general practices...
  20. ncbi Esomeprazole for the management of upper gastrointestinal symptoms in patients who require NSAIDs: a review of the NASA and SPACE double-blind, placebo-controlled studies
    Christopher J Hawkey
    Institute of Clinical Research, Wolfson Digestive Diseases Centre, University Hospital, Nottingham, UK
    Clin Drug Investig 29:677-87. 2009
    ..e. short-term resolution plus long-term prevention of relapse) of upper GI symptoms in users of continuous daily NSAIDs...
  21. ncbi Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole
    Christopher J Hawkey
    Wolfson Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom
    Clin Gastroenterol Hepatol 6:536-44. 2008
    ..We investigated whether lumiracoxib would reduce small-bowel injury compared with naproxen plus omeprazole...
  22. ncbi Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Even
    C J Hawkey
    Wolfson Digestive Diseases Centre, University Hospital Nottingham, Nottingham, UK
    Aliment Pharmacol Ther 27:838-45. 2008
    ..d. (4x the recommended dose in osteoarthritis) vs. naproxen 500 mg b.d. or ibuprofen 800 mg t.d.s...
  23. ncbi Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study
    Christopher J Hawkey
    Wolfson Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom
    Gastroenterology 133:57-64. 2007
    ..Data from the Therapeutic Arthritis Research and Gastrointestinal Event Trial were used to identify risk factors and investigate the safety of lumiracoxib in subgroups...
  24. ncbi Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies
    Christopher J Hawkey
    Institute of Clinical Research, Trials Unit, Wolfson Digestive Diseases Centre, University Hospital, Derby Road, Nottingham, NG7 2UH, UK
    Arthritis Res Ther 9:R17. 2007
    ..The frequency of adverse events was similar in the three groups. Esomeprazole maintains relief of NSAID-associated upper GI symptoms in patients taking continuous NSAIDs, including selective COX-2 inhibitors...
  25. ncbi Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention
    C J Hawkey
    Division of Gastroenterology, University Hospital, Nottingham, UK
    Lancet 352:1016-21. 1998
    ..We investigated the effects of H. pylori eradication in patients with current or previous peptic ulceration, dyspepsia, or both who continued to use NSAIDs...
  26. ncbi Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs
    C J Hawkey
    Institute of Clinical Research Trials Unit, University Hospital, Nottingham, UK
    Aliment Pharmacol Ther 25:813-21. 2007
    ..The use of non-steroidal anti-inflammatory drugs (NSAIDs) is often associated with upper gastrointestinal symptoms such as heartburn and acid regurgitation...
  27. ncbi Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics
    C J Hawkey
    University Hospital, Nottingham, UK
    Aliment Pharmacol Ther 20:51-63. 2004
    ..Previous outcomes studies have, variously, lacked power to investigate this endpoint, focused on broader outcomes, or been too small to quantify the influence of aspirin...
  28. ncbi What do we do about Helicobacter pylori?
    C J Hawkey
    University Hospital, Nottingham, Canada
    Can J Gastroenterol 13:143-5. 1999
    ..Eradication trials have yielded differing results. However, those who have studied patients who have a past history of ulcer disease and are already established on NSAIDs have shown no benefit from H pylori eradication...
  29. ncbi NSAIDs, coxibs, and the intestine
    C J Hawkey
    Wolfson Digestive Diseases Centre, University Hospital, Nottingham NG7 2UH, UK
    J Cardiovasc Pharmacol 47:S72-5. 2006
    ..However, many of these have principally involved Crohn's disease and there have not been enough to be clear whether they affect the influence of relapse of ulcerative colitis...
  30. ncbi Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs
    C J Hawkey
    Wolfson Digestive Diseases Centre, Institute of Clinical Research, University Hospital, Nottingham, UK
    Br J Clin Pharmacol 61:730-7. 2006
    ..Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are also effective COX-2 inhibitors, so we investigated the hypothesis that they too increase risk of MI...
  31. ncbi Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans
    C J Hawkey
    Division of Gastroenterology, University Hospital Nottingham, Nottingham, UK
    Gut 52:1537-42. 2003
    ....
  32. ncbi Gastrointestinal safety of selective COX-2 inhibitors
    C J Hawkey
    Division of Gastroenterology, Queen s Medical Centre, University Hospital Nottingham, Nottingham, UK
    Curr Pharm Des 8:1077-89. 2002
    ..g. patients who are elderly, on aspirin or corticosteroids, have a previous ulcer or have H. pylori infection...
  33. ncbi Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract
    Martin W James
    Wolfson Digestive Diseases Centre, University Hospital Nottingham, Nottingham NG7 2UH
    Br J Clin Pharmacol 56:146-55. 2003
    ..This review article analyzes the quantitative techniques that can be employed by clinical pharmacologists and the clinical studies performed to assess NSAID damage in the gastrointestinal tract...
  34. ncbi NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective
    C J Hawkey
    Division of Gastroenterology, University Hospital Nottingham, Queen s Medical Centre, Nottingham NG7 2UH, UK
    Clin Exp Rheumatol 19:S23-30. 2001
    ..A helpful development would be more standardized gastrointestinal assessment at the time of ulcer complications and this could be achieved if studies were done in countries with well-developed primary care systems...
  35. ncbi Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study
    Clare Atherton
    Division of Gastroenterology, University Hospital, Nottingham, United Kingdom
    Clin Gastroenterol Hepatol 2:113-20. 2004
    ..CONCLUSIONS: Lumiracoxib is a potent selective inhibitor of COX-2 that causes little or no endoscopically detected stomach or duodenal injury or changes in bowel permeability...
  36. ncbi Gastrointestinal safety of COX-2 specific inhibitors
    C J Hawkey
    Division of Gastroenterology, University Hospital, Nottingham, United Kingdom
    Gastroenterol Clin North Am 30:921-36. 2001
    ..Contrary to current popular truisms, the greatest value of coxibs may be in patients without risk factors because it is in this unconfounded group that the ability of coxibs to free patients of ulcer risk appears to be delivered in full...
  37. ncbi Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding
    W A Stack
    Division of Gastroenterology, University Hospital, Nottingham, UK
    Aliment Pharmacol Ther 16:497-506. 2002
    ..pylori infection is associated with an increased risk of ulcer bleeding. The risk from non-aspirin NSAIDs is even higher, but is less in H. pylori infected people. Low-dose aspirin is now commonly associated with ulcer bleeding...
  38. ncbi Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production
    N J Wight
    Division of Gastroenterology, University Hospital, Nottingham, England
    Gastroenterology 120:867-73. 2001
    ..002 vs. placebo), but rofecoxib only inhibited COX-2-dependent LPS-induced PGE(2) (by 79%; P < 0.001 vs. placebo). CONCLUSIONS: Rofecoxib (50 mg) lacked naproxen's ability to reduce the availability of gastroprotective prostaglandins...
  39. ncbi Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
    Michael E Farkouh
    Cardiovascular Clinical Research Center, New York University School of Medicine, 530 First Avenue, New York, NY 10016, USA
    Lancet 364:675-84. 2004
    ....
  40. ncbi Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis
    Loren Laine
    University of Southern California School of Medicine, Los Angeles, California 90033, USA
    Gastroenterology 123:1006-12. 2002
    ....
  41. ncbi Physiology and organ-related pathology of the elderly: stomach ulcers
    J I Jones
    Divison of Gastroenterology, University Hospital, Nottingham NG7 2UH, UK
    Best Pract Res Clin Gastroenterol 15:943-61. 2001
    ..There is still potential for the development of new strategies to prevent primary and secondary ulcers, either by new drug development or by expanding existing co-prescription strategies...
  42. ncbi Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial
    Thomas J Schnitzer
    Office of Clinical Research and Training, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Lancet 364:665-74. 2004
    ....
  43. ncbi COX-1 and COX-2 inhibitors
    C J Hawkey
    Division of Gastroenterology, University Hospital Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK
    Best Pract Res Clin Gastroenterol 15:801-20. 2001
    ..The VIGOR study has raised the possibility that some NSAIDs, particularly naproxen, may protect against vascular disease compared to COX-2 inhibitors (or placebo)...
  44. ncbi Cyclooxygenase-2 inhibitors
    Christopher J Hawkey
    Wolfson Digestive Diseases Centre, University of Nottingham, University Hospital, UK
    Curr Opin Gastroenterol 21:660-4. 2005
    ..The purpose of this review is to summarize new information regarding the use of selective inhibitors of the cyclooxygenase-2 enzyme, emphasizing recent developments regarding cardiovascular risk...
  45. ncbi Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points
    G M Hawkey
    Division of Gastroenterology, University Hospital, Nottingham NG7 2UH, UK
    Gut 49:372-9. 2001
    ..09-0.81)), although there was no evidence of synergy. CONCLUSIONS: Blood in the stomach reflects clinical features in patients with acute upper gastrointestinal bleeding and is reduced by treatment with lansoprazole and tranexamic acid...
  46. ncbi Life after Vioxx: the clinical implications
    P J Fortun
    Wolfson Digestive Diseases Centre, Institute of Clinical Research, University of Nottingham, Nottingham NG7 2UH
    Hosp Med 66:264-7. 2005
  47. ncbi Characterization of etoricoxib, a novel, selective COX-2 inhibitor
    Aimee Dallob
    Clinical Development Laboratory, Merck Research Laboratories, Rahway, New Jersey, USA
    J Clin Pharmacol 43:573-85. 2003
    ....
  48. ncbi Response to expression of concern regarding VIGOR study
    Claire Bombardier
    N Engl J Med 354:1196-9. 2006
  49. ncbi Nonsteroidal antiinflammatory drugs and the small intestine
    Paul J Fortun
    University of Nottingham, Queens Medical Centre, Nottingham, UK
    Curr Opin Gastroenterol 23:134-41. 2007
    ..Two-thirds of regular nonsteroidal antiinflammatory drug users develop subclinical small bowel enteropathy. This review highlights this emerging issue in patients requiring antiinflammatory drugs...
  50. ncbi Update in the pharmacological management of peptic ulcer haemorrhage
    A K Kubba
    Dept of Surgery and Gastroenterology, University of Nottingham, UK
    Scand J Gastroenterol 36:337-42. 2001
    ..The only other drug which may be useful in selected patients is octreotide, but its universal use cannot be recommended...
  51. ncbi Comparison of high definition with standard white light endoscopy for detection of dysplastic lesions during surveillance colonoscopy in patients with colonic inflammatory bowel disease
    Venkataraman Subramanian
    Department of Gastroenterology and Leeds Institute of Molecular Medicine, St James University Hospital, Leeds, UK Nottingham Digestive Diseases Centre, Nottingham University Hospital, UK Venkataraman Subramanian was the recipient of an NIHR clinical lecturership from the National Institute of Health Research UK Krish Ragunath has received educational grant support from Olympus Keymed, UK
    Inflamm Bowel Dis 19:350-5. 2013
    ..The utility of HD colonoscopy in dysplasia detection in patients with IBD has not been reported so far. We aimed to compare the yield of dysplastic lesions detected by standard definition (SD) white light endoscopy with HD endoscopy...
  52. ncbi Diagnosis of autoimmune gastritis by high resolution magnification endoscopy
    George K Anagnostopoulos
    Wolfson Digestive Diseases Centre, University Hospital, Nottingham, NG7 2UH, United Kingdom
    World J Gastroenterol 12:4586-7. 2006
    ..Using this technique we were able to describe the normal gastric microvasculature pattern and we also identified characteristic patterns in two cases of autoimmune atrophic gastritis...
  53. ncbi Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: a randomized controlled trial. The Platelet Activating Factor Antagonist Study Group in Ulcerative Colitis
    W A Stack
    Department of Gastroenterology, University Hospital, Queens Medical Centre, Nottingham, England
    Gastroenterology 115:1340-5. 1998
    ..In animal models of experimental colitis, specific inhibition of PAF has reduced inflammation. The aim of this study was to evaluate the efficacy and safety of the PAF antagonist SR27417A in moderately active UC...
  54. ncbi Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model
    A E Duggan
    Department of Public Health and Epidemiology, University of Nottingham, Nottingham NG7 2UH
    BMJ 316:1648-54. 1998
    ..To determine how small differences in the efficacy and cost of two antibiotic regimens to eradicate Helicobacter pylori can affect the overall cost effectiveness of H pylori eradication in duodenal ulcer disease...
  55. ncbi A novel flow cytometric assay for quantitating adherence of Helicobacter pylori to gastric epithelial cells
    R P Logan
    Division of Gastroenterology, University Hospital, Nottingham, UK
    J Immunol Methods 213:19-30. 1998
    ..Fluorescent labelling of H. pylori with CFDA-SE in combination with flow cytometry provides a quick, specific, and sensitive method to quantitate in vitro the adherence of H. pylori...
  56. ncbi Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis
    W A Stack
    Division of Gastroenterology, University Hospital, Queens Medical Centre, Nottingham, UK
    Aliment Pharmacol Ther 12:973-8. 1998
    ..Although cyclosporin appears to be effective in reducing colectomy rates in the short term, few data are available on the long-term follow-up of such patients...
  57. ncbi Simple and accurate PCR-based system for typing vacuolating cytotoxin alleles of Helicobacter pylori
    J C Atherton
    Department of Medicine, Division of Gastroenterology, University Hospital, University of Nottingham, Nottingham, United Kingdom
    J Clin Microbiol 37:2979-82. 1999
    ..pylori and show that this system correctly identifies the signal and midregion types of vacA in 77 strains from Asia and North and South America...
  58. ncbi Is Helicobacter pylori eradication useful in patients taking NSAIDs?
    C J Hawkey
    Division of Gastroenterology, University Hospital, Queen s Medical Centre, Nottingham, UK
    Eur J Gastroenterol Hepatol 11:S47-50; discussion S73. 1999
    ..H. pylori eradication did not prevent ulcer recurrence during a six-month assessment; indeed, it retarded healing of gastric ulcers. The hypothesis that dyspepsia would be prevented by H. pylori eradication was not confirmed either...
  59. ncbi COX-LOX inhibition: current evidence for an emerging new therapy
    M M Skelly
    Division of Gastroenterology, University Hospital, Queen's Medical Centre, Nottingham NG7 2UH, UK
    Int J Clin Pract 57:301-4. 2003
    ..This review examines the hypothesis that licofelone is an effective anti-inflammatory agent that does not cause peptic damage...
  60. ncbi Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?
    L J Tata
    Epidemiology and Public Health, University of Nottingham, City Hospital, Nottingham, UK
    Aliment Pharmacol Ther 22:175-81. 2005
    ..Recent guidance cautions against concurrent prescription, particularly in older people...
  61. ncbi Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users
    C J Hawkey
    Division of Gastroenterology, University Hospital Nottingham, Queen s Medical Centre, Nottingham, UK
    Gut 51:344-50. 2002
    ..Factors predisposing to endoscopic ulcer formation or healing with non-steroidal anti-inflammatory drugs (NSAIDs) have not been well defined...
  62. ncbi Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs
    C J Hawkey
    Division of Gastroenterology, University Hospital, Queen s Medical Centre, Nottingham, UK
    Gut 51:336-43. 2002
    ..Whether this is due to Helicobacter pylori infection or to reactivation of the original lesion is unclear...
  63. ncbi Eradicating Helicobacter pylori in patients with a past history of peptic ulcer: is the juice worth the squeeze?
    A Duggan
    Division of Epidemiology, Queen s Medical Centre, University of Nottingham, United Kingdom
    J Qual Clin Pract 21:76-9. 2001
    ..Eradicating H. pylori in patients with a past history of peptic ulcer disease not associated with non-steroidal anti-inflammatory drug ingestion is a challenging goal in general practice...
  64. ncbi Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease
    V Subramanian
    Nottingham Digestive Diseases Centre, Nottingham University Hospital, UK
    Aliment Pharmacol Ther 33:304-12. 2011
    ..Dysplasia in inflammatory bowel disease (IBD) is often multifocal and flat. Dye spraying is believed to enhance visualisation of subtle mucosal abnormalities...
  65. ncbi Efficacy of new playback functions at reducing small-bowel wireless capsule endoscopy reading times
    Venkataraman Subramanian
    Nottingham Digestive Diseases Centre, Nottingham University Hospital Queens Medical Centre, Nottingham, UK
    Dig Dis Sci 57:1624-8. 2012
    ..The clinical efficacy of these new playback features is unknown. Our objective was to evaluate the diagnostic yield and reading times of these new playback features...
  66. ncbi Induction of a chemoattractant transcriptional response by a Campylobacter jejuni boiled cell extract in colonocytes
    Kenneth H Mellits
    Division of Food Sciences, School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, Leicestershire, LE12 5RD, UK
    BMC Microbiol 9:28. 2009
    ....
  67. ncbi Dual COX inhibition and upper gastrointestinal damage
    M M Skelly
    Division of Gastroenterology, University Hospital, Queen's Medical Centre, Nottingham, UK
    Curr Pharm Des 9:2191-5. 2003
    ..Balanced cyclooxygenase/lipoxygenase inhibition maybe less harmful than cyclooxygenase inhibition. Also, nitric oxide can subserve many of the protective effects of prostaglandins and NO-donating NSAIDs are under evaluation...
  68. ncbi Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs
    N Hudson
    Department of Medicine, University Hospital, Nottingham
    Gut 34:742-7. 1993
    ..001). Enhanced gastric mucosal synthesis of LTB4 in patients taking NSAIDs may represent a primary effect of these drugs and could be implicated in the pathogenesis of gastritis and ulceration associated with NSAIDs...
  69. ncbi Failure of ethamsylate to reduce aspirin-induced gastric mucosal bleeding in humans
    T K Daneshmend
    Department of Therapeutics, University Hospital, Nottingham
    Br J Clin Pharmacol 28:109-12. 1989
    ..1 (8.5-23.4) microliters 10 min-1] was not significantly different from that after aspirin alone. 5. We conclude that ethamsylate does not reduce acute aspirin-induced gastric mucosal bleeding in healthy humans...
  70. ncbi Disruption of colonic barrier function and induction of mediator release by strains of Campylobacter jejuni that invade epithelial cells
    Johannes Beltinger
    Wolfson Digestive Diseases Centre, Nottingham University Hospital, QMC Campus, Nottingham NG7 2UH, United Kingdom
    World J Gastroenterol 14:7345-52. 2008
    ..To study the mechanisms by which Campylobacter jejuni (C. jejuni) causes inflammation and diarrhea. In particular, direct interactions with intestinal epithelial cells and effects on barrier function are poorly under-stood...
  71. ncbi Comparison of high-resolution magnification narrow-band imaging and white-light endoscopy in the prediction of histology in Barrett's oesophagus
    Rajvinder Singh
    Wolfson Digestive Diseases Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK
    Scand J Gastroenterol 44:85-92. 2009
    ....
  72. ncbi Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease
    Maeve M Skelly
    Division of Gastroenterology, Department of Pathology, University Hospital, Queen s Medical Center, Nottingham, NG7 2UH, England, U K
    Inflamm Bowel Dis 8:93-7. 2002
    ..Moreover, as patients with UC may be unduly prone to colonic injury, MMF may not be a suitable drug for its treatment...
  73. ncbi Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells
    M A Hull
    Division of Gastroenterology, University Hospital, Queen s Medical Centre, Nottingham, UK
    Gut 45:529-36. 1999
    ..The mechanism whereby NSAIDs inhibit granulation tissue angiogenesis is unknown but may involve inhibition of either or both COX isoforms (COX-1 and COX-2)...
  74. ncbi Nocardia asteroides lung abscess in acute ulcerative colitis treated with cyclosporine
    W A Stack
    Division of Gastroenterology, University Hospital, Nottingham, United Kingdom
    Am J Gastroenterol 96:2255-6. 2001
    ..With increasing use of cyclosporine for acute UC it is to be anticipated that opportunistic infections such as Nocardia will be more frequently encountered in the future...
  75. ncbi Guest authorship, mortality reporting, and integrity in rofecoxib studies
    Christopher J Hawkey
    JAMA 300:901; author reply 904-5. 2008
  76. ncbi Ratio of visceral to subcutaneous fat area is a biomarker of complicated Crohn's disease
    Bara Erhayiem
    Nottingham Digestive Diseases Centre, Nottingham University Hospital, United Kingdom
    Clin Gastroenterol Hepatol 9:684-687.e1. 2011
    ..We investigated whether a higher ratio of visceral to subcutaneous fat was associated with complicated (fistulating or stricturing) CD...
  77. ncbi Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon
    Shri Pathmakanthan
    Division of Gastroenterology, University Hospital, Queens Medical Centre, Nottingham, UK
    J Gastroenterol Hepatol 19:166-73. 2004
    ....
  78. ncbi Characterization of cullin-based E3 ubiquitin ligases in intact mammalian cells--evidence for cullin dimerization
    Eng Hui Chew
    Wolfson Digestive Diseases Centre, University of Nottingham, Queen s Medical Centre, Nottingham, NG7 2UH, UK
    Cell Signal 19:1071-80. 2007
    ..Cul3, but not Cul1 homooligomerization is dependent on substrate recognition subunit dimer formation. As shown for other E3 ubiquitin ligases, dimerization may play a role in regulating the activity of cullin-based E3 ligases...
  79. ncbi Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2
    Y R Mahida
    Division of Gastroenterology, University Hospital, Queen s Medical Centre, Nottingham, United Kingdom
    Am J Physiol 273:G1341-8. 1997
    ..Adult human colonic subepithelial myofibroblasts may influence epithelial cell function via products of COX-1 and -2 enzymes, such as PGE2 and secreted ECM proteins...
  80. ncbi A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease
    J C Mansfield
    Department of Gastroenterology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
    Aliment Pharmacol Ther 26:421-30. 2007
    ..It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease...
  81. ncbi Twenty-four-hour intragastric acidity and clinical trial of bedtime enprostil 70 micrograms compared with ranitidine 300 mg in duodenal ulcer
    R P Walt
    Department of Therapeutics, City Hospital, Nottingham, UK
    Aliment Pharmacol Ther 1:161-6. 1987
    ..0007). However, 6 months after cessation of treatment there was no material difference in overall outcome. Despite combining mucosal protection with acid inhibition enprostil treatment conferred no advantage over simple acid inhibition...
  82. ncbi Acetic acid-enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus
    P J Fortun
    Wolfson Digestive Diseases Centre, and Department of Histopathology, Queen's Medical Centre, University Hospital, Nottingham, UK
    Aliment Pharmacol Ther 23:735-42. 2006
    ..CONCLUSIONS: Enhanced magnification endoscopy allows clear visualization of the epithelial pit patterns within Barrett's oesophagus, and targeted biopsy results in a high yield of specialized intestinal metaplasia and dysplasia...
  83. ncbi 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease
    Y R Mahida
    Department of Therapeutics, Queen s Medical Centre, Nottingham
    Gut 32:50-4. 1991
    ..At the doses studied, 5 aminosalicylic acid also reduced the amount of leukotriene B4 detected after culture...
  84. ncbi Isolated crypts form spheres prior to full intestinal differentiation when grown as xenografts: an in vivo model for the study of intestinal differentiation and crypt neogenesis, and for the abnormal crypt architecture of juvenile polyposis coli
    Raffaele Del Buono
    Histopathology Unit, Cancer Research (UK, London Research Institute, London, UK
    J Pathol 206:395-401. 2005
    ....
  85. ncbi Glutathione S-transferase M1 polymorphism and metabolism of sulforaphane from standard and high-glucosinolate broccoli
    Amy V Gasper
    Phytochemicals and Health Programme, Institute of Food Research, Norwich Research Park, Colney, Norwich, United Kingdom
    Am J Clin Nutr 82:1283-91. 2005
    ..The potential consequences of consuming glucosinolate-enriched broccoli for GSTM1-null and -positive persons are discussed...
  86. ncbi Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett's esophagus: a meta-analysis
    J Mannath
    Nottingham Digestive Diseases Centre, NIHR Biomedical Research Unit, Queens Medical Centre Campus, University of Nottingham, UK
    Endoscopy 42:351-9. 2010
    ..We aimed to assess the diagnostic accuracy of NBI with magnification for the diagnosis of high grade dysplasia (HGD) and specialized intestinal metaplasia (SIM) in patients with Barrett's esophagus...
  87. ncbi Narrow-band imaging with magnification in Barrett's esophagus: validation of a simplified grading system of mucosal morphology patterns against histology
    R Singh
    Wolfson Digestive Diseases Centre, Queen s Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK
    Endoscopy 40:457-63. 2008
    ....
  88. ncbi Consuming broccoli does not induce genes associated with xenobiotic metabolism and cell cycle control in human gastric mucosa
    Amy V Gasper
    Phytochemicals and Health Programme, Institute of Food Research, Colney, Norwich NR4 7UA, UK
    J Nutr 137:1718-24. 2007
    ..Only 1 such gene was significantly up-regulated after consumption of standard broccoli. The consequences of these results in relation to the potential anticarcinogenic action of broccoli are discussed...